VEGFA and neoplasm: In particular, the potential for low-dose anti-VEGF therapy to prune immature tumour vessels and enhance functionality of the remaining vasculature for improved chemo- and radiation therapies was recognized and has shown promising outcomes in preclinical and clinical studies (11).